Conbercept
Conbercept, sold under the commercial name Lumitin, is a novel vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). The anti-VEGF was approved for the treatment of neovascular AMD by the China State FDA (CFDA) in December 2013. As of December 2020, conbercept is undergoing phase III clinical trials through the U.S. Food and Drug Administration’s PANDA-1 and PANDA-2 development programs.
Link from a Wikipage to another Wikipage
primaryTopic
Conbercept
Conbercept, sold under the commercial name Lumitin, is a novel vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). The anti-VEGF was approved for the treatment of neovascular AMD by the China State FDA (CFDA) in December 2013. As of December 2020, conbercept is undergoing phase III clinical trials through the U.S. Food and Drug Administration’s PANDA-1 and PANDA-2 development programs.
has abstract
Conbercept, sold under the com ...... rketed under the name Lumitin.
@en
alternative name
Lumitin
@en
CAS number
1227158-72-6
FDA UNII code
1P05PW62F3
Link from a Wikipage to an external page
Wikipage page ID
66,240,342
page length (characters) of wiki page
Wikipage revision ID
1,025,335,115
Link from a Wikipage to another Wikipage
CAS number
molecular weight
routes of administration
Intravitreal Injection
@en
tradename
Lumitin
@en
wikiPageUsesTemplate
comment
Conbercept, sold under the com ...... PANDA-2 development programs.
@en
label
Conbercept
@en